Abstract

We report a case of a female with stage I infiltrating ductal carcinoma who received adjuvant therapy including trastuzumab. One year later she developed lytic lesions and was retreated with trastuzumab that was held after she developed symptomatic heart failure. Lytic lesions were attributed to relapse of breast cancer, and cardiac failure attributed to prior trastuzumab therapy. After complications necessitated multiple hospitalizations, a further workup revealed that the lytic lesions were not metastatic breast cancer but multiple myeloma. Her advanced multiple myeloma was associated with systemic amyloidosis involving gut and heart, which ultimately led to her demise. This report addresses the pitfalls of overlapping symptoms and the question of which patients with suspected metastatic disease should undergo a biopsy.

Highlights

  • We report a case of a female with stage I infiltrating ductal carcinoma who received adjuvant therapy including trastuzumab

  • Her advanced multiple myeloma was associated with systemic amyloidosis involving gut and heart, which led to her demise

  • Given that there are no clear guidelines about which patients and which tumors require biopsy for verification of metastases, each diagnosis of metastasis should be carefully evaluated for the likelihood of association with the primary tumor

Read more

Summary

Introduction

We report a case of a female with stage I infiltrating ductal carcinoma who received adjuvant therapy including trastuzumab. Lytic lesions were attributed to relapse of breast cancer, and cardiac failure attributed to prior trastuzumab therapy. After complications necessitated multiple hospitalizations, a further workup revealed that the lytic lesions were not metastatic breast cancer but multiple myeloma.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call